Characteristics

Total (N = 62)

Outcomes

Died (n_d = 25)

Survived (n_s = 37)

P-value

A. Demography

Age in years

58.29 ± 10.17

60.24 ± 10.27

56.97 ± 10.03

0.21

Gender

Male

33 (100.00)

16 (48.50)

17 (51.50)

0.11

Female

28 (100.00)

8 (28.60)

20 (71.40)

B. Predisposing Factors

Diabetes mellitus status

Without

3 (100.00)

0 (0.00)

3 (100.00)

0.03*

Recently diagnosed

19 (100.00)

5 (26.30)

14 (73.70)

Uncontrolled

10 (100.00)

2 (20.00)

8 (80.00)

Controlled

23 (100.00)

14 (60.90)

9 (39.10)

Diabetes mellitus drug-use

None

23 (100.00)

5 (21.70)

18 (78.30)

0.11

Antidiabetic agent

22 (100.00)

11 (50.00)

11 (50.00)

On insulin

4 (100.00)

2 (50.00)

2 (50.00)

Both

6 (100.00)

4 (66.70)

2 (33.30)

Diabetes mellitus duration in years

5.85 ± 6.42

8.59 ± 7.02

4.03 ± 5.35

0.007**

C. Laboratory Test Results

Leucocyte

12.44 ± 5.52

14.79 ± 5.06

10.85 ± 5.31

0.003**

Lymphocyte

1427.97 ± 1338.71

1154.00 ± 923.68

1613.08 ± 1542.90

0.07

D. COVID-19-related Factors and Treatments

COVID-19 Severity

Mild

14 (100.00)

8 (57.10)

6 (42.90)

0.07

Moderate

31 (100.00)

8 (25.80)

23 (74.20)

Sever

11 (100.00)

6 (54.50)

5 (45.50)

Location of Mucormycosis

Nasal/sinus

9 (100.00)

5 (55.60)

4 (44.40)

0.04*

Rhino-orbital

28 (100.00)

7 (25.00)

21 (75.00)

Rhino-orbital-cerebral

22 (100.00)

13 (59.10)

9 (40.90)

Corticosteroid Therapy

No

1 (100.00)

1 (100.00)

0 (0.00)

0.41

Yes

53 (100.00)

21 (39.60)

32 (60.40)

Hospitalisation Status

Inpatient

19 (100.00)

10 (52.60)

9 (47.40)

0.19

Outpatient

43 (100.00)

15 (34.90)

28 (65.10)

Vaccination Status

No dose

32 (100.00)

14 (43.80)

18 (56.20)

0.77

First dose

20 (100.00)

7 (35.00)

13 (65.00)

Completed

4 (100.00)

2 (50.00)

2 (50.00)

Debridement Surgery

No

2 (100.00)

1 (50.00)

1 (50.00)

0.78

Yes

60 (100.00)

24 (40.00)

36 (60.00)

Medical Treatment

No

13 (100.00)

6 (46.20)

7 (53.80)

0.63

Yes

49 (100.00)

19 (38.80)

30 (61.20)